推薦產品
等級
certified reference material
品質等級
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商／商標名
Cerilliant®
濃度
100 μg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
forensics and toxicology
格式
single component solution
儲存溫度
−20°C
SMILES 字串
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56
InChI
1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1
InChI 密鑰
YOYLLRBMGQRFTN-IOMBULRVSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
Norbuprenorphine is the primary active metabolite of the opiate buprenorphine in urine. This Certified Spiking Solution® is suitable as a starting material for use as calibrators and controls in GC/MS and LC/MS methods in forensic analysis, clinical toxicology, urine drug testing, or pain prescription monitoring. Buprenorphine, sold under trade names such as Buprenex®, Subutex® and Suboxone®, is an opiate drug used to treat opioid addiction and to moderate acute pain.
應用
- Norbuprenorphine solution for opioid receptor research: A study analyzed the pharmacokinetics of buprenorphine and its metabolite norbuprenorphine in neutered male cats anesthetized with isoflurane, highlighting its role in opioid receptor agonist research and the impact on pain management strategies (Pypendop et al., 2023).
- Metabolite solution for biochemistry experiments: A study addressed the quantitative analysis of buprenorphine and norbuprenorphine levels in urine, demonstrating norbuprenorphine′s application in biochemistry experiments to understand opioid use disorder and its treatment (Holt et al., 2018).
法律資訊
Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
49.5 °F - closed cup
閃點（°C）
9.7 °C - closed cup
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Marta Concheiro et al.
Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)
Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant
Hong K Kim et al.
Pediatrics, 130(6), e1700-e1703 (2012-11-07)
Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use
Giuseppe Lippi et al.
Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory
Tor Seldén et al.
Forensic science international, 220(1-3), 284-290 (2012-05-09)
Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務